-+ 0.00%
-+ 0.00%
-+ 0.00%

Whitehawk Therapeutics publishes ovarian cancer MUC16 expression study presentation

PUBT·04/12/2026 16:22:14
Listen to the news
Whitehawk Therapeutics publishes ovarian cancer MUC16 expression study presentation
  • Whitehawk Therapeutics published a medical research presentation on MUC16 expression patterns in ovarian cancer to support development of MUC16-targeted antibody-drug conjugates.
  • Analysis cited MUC16 overexpression in about 80% of epithelial ovarian cancers, with limited expression in normal tissue.
  • Data showed MUC16 protein abundance in serous ovarian carcinoma tumor samples was 1.35-fold higher than normal adjacent tissue.
  • RNA-sequencing results across 5,227 ovarian cancer tumors showed robust expression across histologic subtypes, with lowest median expression in mucinous adenocarcinoma.
  • Whitehawk’s investigational MUC16-targeted ADC, HWK-016, is in a phase 1 trial for advanced gynecological cancers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on April 12, 2026, and is solely responsible for the information contained therein.